Discussion
tumor, HRD
TUMOR
Assessment of HRD status is mandatory to balance benefit and risks of PARPi maintenance in newly diagnosed AOC patients. We report here clinical validation of Analysis of the discordant cases between The clinical value of HRD testing may not be restricted to the question of ola in AOC. Contrary to ola, which has not been authorized in first line for HRP cases (alone or in combination with bev), niraparib has obtained an “all-comers” approval. However, the subgroup analysis of the PRIMA trial showed a smaller magnitude of benefit with niraparib in the HRP subgroup, as determined by MyChoice (HR: 0.68 versus 0.40 in HRP and HRD, respectively, with median PFS of 8.1 and 5.4 months with or without niraparib in the HRP subgroup, respectively), limiting the clinical benefit for patients in this situation [Other teams also participated in the EHEI and the new tests detecting HRD have been validated on tumor samples from the PAOLA-1 trial [In conclusion, academic decentralized 